Business Context and Reporting Period
This Form 8-K was filed by Alkermes Plc. on December 5, 2014, reporting events occurring on December 3, 2014. The filing details the approval of the Fiscal Year 2015 Reporting Officer Performance Pay Plan by the Compensation Committee of the Board of Directors.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on executive compensation structures and performance objectives rather than financial results.
Material Changes
The primary material change reported is the establishment of a new performance pay plan for fiscal year 2015 (January 1, 2015, to December 31, 2015). This plan defines compensation ranges and targets for nine reporting officers, including the CEO, President, and various Senior Vice Presidents.
Guidance, Outlook, and Management Commentary
The Compensation Committee established eight specific Performance Objectives for fiscal year 2015, which serve as the basis for executive payouts:
- Secure NDA approval for aripiprazole lauroxil.
- Execute on development plans for pipeline products.
- Execute commercial plans and successfully launch aripiprazole lauroxil.
- Manufacture commercial products and clinical trial material to meet quality, reliability, and efficiency goals.
- Achieve financial guidance.
- Further develop infrastructure and resources to support Company initiatives.
- Manage relationships with key business partners and evaluate new business opportunities.
- Respond to changing business conditions.
Compensation Structure:
- CEO (Richard F. Pops): Target award of 100% of base salary; range of 0% to 200%.
- President (Shane Cooke): Target award of 75% of base salary; range of 0% to 150%.
- Other Participants: Target award of 50% of base salary; range of 0% to 100%.
Awards are contingent on active employment at the time of payment, which occurs within two and one-half months after the end of the fiscal year. The Committee reserves the right to modify the plan or objectives during the fiscal year.
Investor Verification Checklist
- Verify the specific base salary figures for the CEO, President, and other officers to calculate potential total compensation exposure.
- Monitor the regulatory status of aripiprazole lauroxil, as NDA approval is a primary performance objective.
- Review future filings for any modifications to the Performance Objectives or payout ranges as permitted by the Committee.
- Confirm the company's ability to meet the "Achieve financial guidance" objective in subsequent earnings reports.